Document is current
Any future updates will be listed below
-
Authors
Antcliffe, David B.
Peronnet, Estelle
Pène, Frédéric
Strålin, Kristoffer
Brealey, David
Blein, Sophie
Cleaver, Richard
Cronhjort, Maria
Diehl, Jean-Luc
Voiriot, Guillaume
Fleurie, Aurore
Lannsjö, Claudia
Lukaszewicz, Anne-Claire
Mårtensson, Johan
Pham, Tài
De Prost, Nicolas
Ricard, Jean-Damien
Singer, Mervyn
Terraz, Gabriel
Timsit, Jean-François
Unge, Christian
Vieillard-Baron, Antoine
Wahlin, Rebecka Rubenson
Llitjos, Jean-François
Gordon, Anthony C.
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn11364482 at ISRCTN.orgDocuments that mention this clinical trial
An international observational study validating gene-expression sepsis immune subgroups
https://doi.org/10.1186/s13054-025-05319-5
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research Imperial College London Biomedical Research Centre
European Institute of Innovation and Technology
National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
National Institute for Health and Care Research UK (RP-2015-06-018)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 15 February 2025
First Online: 3 March 2025
Declarations
:
: The study gained ethical approval in each participating country: The Health and Care Research Wales research ethics committee (20/LO/1163) in the UK; the Comité de Protection des Personnes Ile de France X in France and the Swedish Ethical Review Authority in Sweden. Written informed consent was provided by participants or their legal representatives following local procedures.
: ACG reports that outside of this work he has received consulting fees from AstraZeneca, Beckman Coulter, and VVB Bio, speaker fees from Fresenius Kabi and grant support from the NIHR HTA programme. DA reports grant support from the NIHR for work outside this project. FP reports that he has received speaker and consulting fees from Gilead outside of this work. JFT reported consulting and lecture fees for bioMerieux unrelated to the submitted work, consulting fees for Merck, Pfizer, Advanz pharma, Menarini, and lecture fees from Merck, Pfizer, Gilead, Mundipharma Qiagen unrelated to the article. JFT also declared research grants to his research group Merck, Pfizer. NP has served as an advisor or speaker for Moderna and AstraZeneca. EP, SB, AF and JFL are bioMerieux employees. EP and SB are co-inventors of patents related to the topic of the manuscript. GV has received research grants form bioMérieux and SOS Oxygène outside of this work, and support for attending meeting from SOS Oxygène and Oxyvie. DB reports lecture fees for bioMérieux unrelated to the submitted work and consulting for Synairgen and Abioinc. JDR has received speaker fees from Fisher&Paykel. TJ-F has received consulting/speaker fees from MSD, Menarini, bioMérieux, Qiagen, Shionogi, Mundipharma and Pfizer. A-CL reports support from bioMérieux for work outside of this project. NDP reports grants, consulting and speaker fees from AstraZeneca and speaker fees from Moderna. MS reports grants from Gentin, consulting fees from Biotest, Matisse, deePull, Volition, Hemotune and Sanofi and speaker fees from bioMérieux and AOP. The authors Dr Antcliffe and Prof Gordon are affiliated with the Department of Health and Social Care, Centre for Antimicrobial Optimization at Imperial College, London. Other authors declare that they have no competing interests.
